Nori Health – Chronic disease management chatbot, launches CE-certified iPhone app
Published on : Tuesday 27-10-2020
Nori Health releases iPhone app for its 8-week digital chatbot coach support program provided to Crohns & Colitis patients.
The Netherlands, October 26, 2020 – Life Science Newswire – Digital health startup Nori Health launched the iPhone app for its digital chronic bowel disease program. The chatbot is initially used by people living with Crohn's or Ulcerative Colitis, with now over 5 million in Europe and the US alone, with expansion to other therapeutic areas planned. Patients can use the CE-certified app to have personal chat conversations with coach Nori to improve lifestyle behaviour and symptoms such as pain, fatigue, and inflammation.
The Nori Health chatbot program provides unlimited conversations over an eight-week period, setting it apart from current behaviour monitoring healthcare apps. These apps leave the responsibility and pressure on the patient to determine what they need to change, in order to get the results they want. With Nori, the digital coach takes the lead, mapping lifestyle patterns and actively suggesting personalized and tailored habit changes.
The chatbot is armed with scientifically-proven data from the get-go, while AI technology is used to continually make Nori smarter, learning from the whole community of users. Patients can get access to program updates twice a year, to receive fresh insights and evaluate their personal situation.
In addition to chat conversations, patients can also indicate signs of a possible inflammation, this is the cause of many cases of hospitalisations and surgery for Crohn's and Colitis patients alike. Nori provides actionable tips for direct relief.
"Patients are guided by a chatbot coach in order to offer personalized support at a large scale, something that is otherwise simply not possible. The number of chronic disease patients is growing fast and this is the way forward in managing this", states Roeland Pater, founder of Nori Health and Crohn's Disease patient.